Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RightHeartIII: Riociguat vs Macitentan in PAH
NCT03362047Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Mar 2018
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat, macitentan in pulmonary arterial hypertension (PAH), sponsored by Justus Liebig University Giessen. Started Mar 2018; status: completed.
02
Drugs
riociguatmacitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03362047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362047.